Results 251 to 260 of about 354,830 (305)
Some of the next articles are maybe not open access.
Vaccine, 1988
There is a great deal of experience on the development and testing of antiviral vaccines but, in the case of HIV, it will be necessary to analyse carefully our understanding of the biology of the organism, the natural history and pathology of the disease (in particular immunity or resistance to infection or clinical symptoms), the possible sources of ...
openaire +2 more sources
There is a great deal of experience on the development and testing of antiviral vaccines but, in the case of HIV, it will be necessary to analyse carefully our understanding of the biology of the organism, the natural history and pathology of the disease (in particular immunity or resistance to infection or clinical symptoms), the possible sources of ...
openaire +2 more sources
Alloantigen-Stimulated Anti-HIV Activity
Blood, 1998AbstractA number of studies have suggested that an immune response to human leukocyte antigen (HLA) alloantigens may contribute to protection against HIV infection. In the present study, we examined the effect of alloantigen-stimulated cell lines obtained from peripheral blood mononuclear cells (PBMC) of HIV-uninfected (HIV−) individuals and the ...
L A, Pinto +3 more
openaire +2 more sources
Boromycin, an Anti-HIV Antibiotic
Bioscience, Biotechnology, and Biochemistry, 1996The polyether-macrolide antibiotic, boromycin, was isolated as a potent anti-human immunodeficiency virus (HIV) antibiotic from a fermentation broth of Streptomyces sp. A-3376. Boromycin was found to strongly inhibit the replication of the clinically isolated HIV-1 strain as well as the cultured strain in in vitro laboratory experiments.
J, Kohno +9 more
openaire +2 more sources
Naturally derived anti‐HIV agents
Phytotherapy Research, 2005AbstractThe urgent need for new anti‐HIV/AIDS drugs is a global concern. In addition to obvious economical and commercial hurdles, HIV/AIDS patients are faced with multifarious difficulties associated with the currently approved anti‐HIV drugs. Adverse effects, the emergence of drug resistance and the narrow spectrum of activity have limited the ...
Asres, Kaleab +4 more
openaire +3 more sources
Pharmacogenetics of Anti-HIV Drugs
Annual Review of Pharmacology and Toxicology, 2008Pharmacogenetics holds promise in HIV treatment because of the complexity and potential toxicity of multidrug therapies that are prescribed for long periods. Thus far, few candidate genes have been examined for a limited number of allelic variants, but a number of confirmed associations have already emerged.
A, Telenti, U M, Zanger
openaire +2 more sources
Anti-HIV-1 and anti-HIV-1-protease substances from Ganoderma Lucidum
Phytochemistry, 1998A new highly oxygenated triterpene named ganoderic acid alpha has been isolated from a methanol extract of the fruiting bodies of Ganoderma lucidum together with twelve known compounds. The structures of the isolated compounds were determined by spectroscopic means including 2D-NMR. Ganoderiol F and ganodermanontriol were found to be active as anti-HIV-
S, el-Mekkawy +8 more
openaire +2 more sources
2002
The use of targeted therapies to treat infectious diseases is a novel application that requires a persistent infection that cannot be cleared by other means and the expression of microbial antigens on the surface of productively-infected cells. Although some bacterial or parasitic infections may meet these criteria, chronic viral infections and microbe-
Seth H. Pincus +2 more
openaire +1 more source
The use of targeted therapies to treat infectious diseases is a novel application that requires a persistent infection that cannot be cleared by other means and the expression of microbial antigens on the surface of productively-infected cells. Although some bacterial or parasitic infections may meet these criteria, chronic viral infections and microbe-
Seth H. Pincus +2 more
openaire +1 more source
1995
(Uploaded by Plazi from the Biodiversity Heritage Library) No abstract provided.
openaire +1 more source
(Uploaded by Plazi from the Biodiversity Heritage Library) No abstract provided.
openaire +1 more source
2008
Modern combination drug therapy has substantially improved the clinical management of HIV-1 infection. Still, the emergence of drug-resistant variants eventually leads to therapy failure in most patients. The selection of an optimal follow-up regimen is complicated by an ever-increasing range of possible drug combinations.
openaire +2 more sources
Modern combination drug therapy has substantially improved the clinical management of HIV-1 infection. Still, the emergence of drug-resistant variants eventually leads to therapy failure in most patients. The selection of an optimal follow-up regimen is complicated by an ever-increasing range of possible drug combinations.
openaire +2 more sources